GHENT, Belgium, 4 January 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it plans to webcast its corporate presentation at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, 11 January 2012 at 03:30 p.m. PST / 00:30 a.m. CET.
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will be webcast live and may be accessed on the home page of the Ablynx website at www.ablynx.com. Shortly thereafter, a replay of the webcast will be available on the Company's website for 30 days following the presentation.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
About AblynxAblynxis a biopharmaceutical company engaged in the discovery and development of Nanobodies ®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over 25 programmes in the pipelineand seven Nanobodies in clinical development. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis, and has had a collaboration with Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over
290 people. More information can be found on www.ablynx.com.
For more information, please contact Ablynx:Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Marieke Vermeersch Investor Relations Manager t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Certain statements, beliefs and opinions in this press
release are forward-looking, which reflect the Company's or,
as appropriate, the Company's directors' current expectations
and projections about future events. By their nature, forward
- looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude
of factors including, but
not limited to, changes in demand, competition and
technology, can cause actual events, performance or results
to differ significantly from any anticipated development.
Forward looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue
in the future. As a result, the Company expressly disclaims
any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press
release as a result of any change in expectations or any
change in events, conditions, assumptions or circumstances on
which these forward-looking statements are based. Neither the
Company nor its advisers or representatives nor any of its or
their parent or subsidiary undertakings or any such person's
officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from
errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained
in this press release or the actual occurrence of the
forecasted developments. You should not place undue reliance
on forward-looking statements, which speak only as of the
date of this press release.
distribué par | Ce noodl a été diffusé par Ablynx NV et initialement mise en ligne sur le site http://www.ablynx.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-04 18:09:24 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 30TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE |